Topical application of the bee hive protectant propolis is well tolerated and improves human diabetic foot ulcer healing in a prospective feasibility study  by Henshaw, Frances R. et al.
Journal of Diabetes and Its Complications 28 (2014) 850–857
Contents lists available at ScienceDirect
Journal of Diabetes and Its Complications
j ourna l homepage: WWW.JDCJOURNAL.COMTopical application of the bee hive protectant propolis is well tolerated
and improves human diabetic foot ulcer healing in a prospective
feasibility studyFrances R. Henshaw a,b, Thyra Bolton b, Vanessa Nube b, Anita Hood b, Danielle Veldhoen b,
Louise Pfrunder b, Genevieve L. McKew a,c, Colin Macleod a,c, Susan V. McLennan a,b, Stephen M. Twigg a,b,⁎
a Sydney Medical School, University of Sydney, Sydney, Australia
b Diabetes Centre, Department of Endocrinology, Royal Prince Alfred Hospital, Sydney, Australia
c Department of Microbiology, Royal Prince Alfred Hospital, Sydney, AustraliaDisclosures: Theauthorshaveno conﬂicts of interest tod
The authors have no conﬂict of interest to declare r
⁎ Correspondingauthor at: SydneyMedical School, TheU
AlfredHospital, Sydney, NSW2006, Australia. Tel.:+612 95
E-mail address: stephen.twigg@sydney.edu.au (S.M.
http://dx.doi.org/10.1016/j.jdiacomp.2014.07.012
1056-8727/© 2014 The Authors. Published by Elseviera b s t r a c ta r t i c l e i n f oArticle history:
Received 12 May 2014
Received in revised form 7 July 2014
Accepted 30 July 2014
Available online 7 August 2014
Keywords:
Diabetic foot ulcer
Propolis
Pilot
MMP-9
Bacteria
Aims: Propolis is a naturally occurring anti-inﬂammatory bee derived protectant resin. We have previously
reported that topically applied propolis reduces inﬂammation and improves cutaneous ulcer healing in
diabetic rodents. The aim of this study was to determine if propolis shows efﬁcacy in a pilot study of human
diabetic foot ulcer (DFU) healing and if it is well tolerated.
Materials: Serial consenting subjects (n = 24) with DFU≥4 week's duration had topical propolis applied at each
clinic review for 6 weeks. Post-debridement wound ﬂuid was analyzed for viable bacterial count and pro-
inﬂammatory MMP-9 activity. Ulcer healing data were compared with a matched control cohort of n = 84 with
comparable DFU treated recently at the same center.
Results: Ulcer area was reduced by a mean 41% in the propolis group compared with 16% in the control group at
week 1 (P b 0.001), and by 63 vs. 44% at week 3, respectively (P b 0.05). In addition, 10 vs. 2% (P b 0.001), then 19
vs. 12% (P b 0.05) of propolis treated vs. control ulcers had fully healed by weeks 3 and 7, respectively. Post-
debridement wound ﬂuid active MMP-9 was signiﬁcantly reduced, by 18.1 vs. 2.8% week 3 from baseline in
propolis treated ulcers vs. controls (P b 0.001), as were bacterial counts (P b 0.001). No adverse effects from
propolis were reported.
Conclusions: Topical propolis is a well-tolerated therapy for wound healing and this pilot in human DFU indicates
for the ﬁrst time that it may enhance wound closure in this setting when appliedweekly. Amulti-site randomized
controlled of topical propolis now appears to be warranted in diabetic foot ulcers.
© 2014 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/3.0/).1. Introduction
Foot ulceration secondary to diabetes occurs in up to one quarter
of people with diabetes (Bentley & Foster, 2007) and it is the
commonest cause of lower limb amputation (Boulton, Vileikyte,
Ragnarson-Tennvall, & Apelqvist, 2005). Diabetes increases the risk of
lower extremity amputation by 10 to 20 times (Wrobel, Mayﬁeld, &
GE, 2005) and the estimated cost to the US healthcare system of
diabetic foot ulceration and related amputations is more than $10.9
billion annually (Shearer, Scuffham, Gordois, Oglesby, & Tobian,eclare related to thismanuscript.
elated to this manuscript.
niversity of Sydney, Royal Prince
156150; fax:+61295161273.
Twigg).
Inc. This is an open access article u2003). Thus diabetic foot ulceration is a cause of signiﬁcant morbidity
and ﬁnancial burden.
The delayed wound healing observed in diabetic foot disease is
attributable to a variety of factors including peripheral arterial
disease, peripheral neuropathy, foot deformity and secondary
bacterial infection (Cavanagh, Lipsky, Bradbury, & Botek, 2005).
Furthermore, the wound microenvironment in diabetes is abnormal
and pathogenic factors lead to delayed ulcer closure, and suboptimal
volume of granulation tissue formation with abnormal extra-cellular
matrix (ECM) composition (Falanga, 2005; Pradhan et al., 2011).
Speciﬁcally, it has been proposed that a persistent inﬂammatory
inﬁltrate also associated with bacterial colonization in the wound
contributes to delayed healing in diabetes (Falanga, 2005).
Propolis is a resinous bee-hive product consisting of plant materials
that are initially collectedon thehind legsofworker bees. Thematerial is
then masticated, salivary enzymes are added and mixed with wax tonder the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).
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2013;Wagh, 2013a). Itsmost biologically active fractions are ﬂavanoids
and esters of caffeic acid (Banskota et al., 2002; Russo, Longo, & Vanella,
2002). Propolis has multiple properties that make it an attractive agent
for treatment of diabetic foot ulcers, including being anti-inﬂammatory
(Grunberger et al., 1988), anti-oxidant (Fonseca et al., 2011; Nagaoka
et al., 2003; Talas et al., 2014) and anti-microbial (Gekker, Hu, Spivak,
Lokensgard, & Peterson, 2005; Mirzoeva, Grishanin, & Calder, 1997)
especially anti-bacterial (Astani et al., 2013; Scheller, Tustanowski,
Kurylo, Paradowski, & Obuszko, 1977), in its actions. Furthermore,
propolis component caffeic acid, has potent activity to inhibit the pro-
inﬂammatory proteinase, matrix metalloproteinase-9 (MMP-9), and
MMP-9 is known to be increased in diabetic foot ulcers (Jin et al., 2005;
Ladwig et al., 2002; Liu et al., 2009).
We have previously published in a preclinical, diabetic rodent
model of full thickness cutaneous wound healing, that a single
application of topical propolis normalized ulcer closure rate and
reduced persistent neutrophil inﬁltration and elastase activity
(McLennan et al., 2008). In humans, propolis has been described as
a useful topical treatment for ulcers (Wagh, 2013b). It is considered to
have a low side-effect proﬁle (Gallo et al., 2014; Rajpara et al., 2009;
Sforcin & Bankova, 2011) and is approved in many countries for
treatment of ulcers and abrasions, being sold over the counter inmany
parts of the world including in Australasia (Wagh, 2013b). However,
despite the longevity and increasing popularity of use of propolis
generally to treat many diseases, no systematic study has been
reported in the use of propolis in humans with diabetic foot ulcers.
The principal aim of the current work in diabetic foot ulcers was to
determine if topically applied propolis on a recurrent basis is well
tolerated and if it demonstrates promise as a wound healing agent.
The potential beneﬁt of propolis treatment in addition to antibiotic
therapy was also investigated.
2. Research design and methods
This study was a prospective, externally (historic) controlled
design. Patients with type 1 or type 2 diabetes attending the High
Risk Foot Service (HRFS) at Royal Prince Alfred Hospital Sydney
across the 2011 calendar year, and who fulﬁlled the study inclusion
criteria, as described below, were invited to take part. The HRFS is a
well-established multidisciplinary foot care service where we have
previously reported outcome data related to wound biomarkers (Liu
et al., 2009) and bacterial counts (Xu et al., 2007) in foot ulcer
healing. In this study, n = 24 serial patients were recruited, while
three other patients declined to take part. The protocol was approved
by the ethics committee of Sydney South West Area Health Service,
NSW, Australia, and informed consent was obtained from each
enrolling patient.
A foot ulcer of 4 weeks' duration ormorewas deemed to be classiﬁed
as a chronic ulcer, as adopted by the American Diabetes Association,
(1999) and included in this study. For study inclusion, patients with a
chronic foot ulcer needed to be at or above 18 years of age, with diabetes
mellitus and able to give informed consent. All ulcers included in the
study were classiﬁed by the established University of Texas grade and
staging system, which predicts ulcer healing outcomes (American
Diabetes Association, 1999). Ulcers were also described as ‘neuropathic’,
‘neuro-ischaemic’ or ‘post-operative/pressure related’, to help distinguish
the type of ulcer category, which as described by others typically have
different healing outcomes (Oyibo et al., 2001). Study exclusion criteria
were: (i) patientswith severe peripheral arterial disease (PAD)deﬁned as
ischemic pain at rest and/or ankle-brachial pressure index (ABPI) at or
below 0.7, as these wounds were deemed unlikely to heal in the absence
of revascularization (Stadelmann &Digenis, 1998); and/or (ii) foot ulcers
with attendant severe infection, deﬁned as those deemed by High Risk
Foot Service medical staff to require intravenous antibiotics and/or
hospital admission.Propolis in aqueous liquid form sourced in Australia, (Honey
Spring Variety, batch number 7232, Vastrade, Lidcombe NSW), was
administered to cover the entire ulcer each time the patient attended
from week 0 in the clinic for 6 weeks, or until the ulcer healed,
whichever occurred ﬁrst. A thin and even coating of propolis was
painted onto the entire wound surface with a sterile cotton bud. The
study personnel (FH) who applied the propolis was not involved in
ongoing patient care, nor in determining ulcer area. The propolis was
applied at the conclusion of each scheduled treatment, just prior to
application of dressings, to minimize any potential bias from any
change in routine care. The average time between visits was
10.5 days, with most individuals being seen weekly or fortnightly
for standard care as is usual practice in the HRFS. This time frame of
application was timed to be in keeping with the usual attendance
times of patients to the Clinic, including the historic controls used in
this study.
Each subject was followed up for a further 6 weeks after propolis
treatment ceased, or until their wound healed, whichever occurred
ﬁrst. At each visit wound area was measured using acetate tracing and
was scanned onto a PC all as previously described (Liu et al., 2009; Xu
et al., 2007), and measured using Bersoft Image Measurement (BIM)
analysis (Bersoft.com). Comparison with previous tracings enabled
wound closure to be determined as a percentage of original wound
area, per unit time.
In addition, on each occasion where an adequate volume of
sample could be obtained (n = 25 μl), following ulcer debridement
but prior to the application of propolis, 2 × 25 μl samples of wound
ﬂuid were obtained from study subjects using a calibrated sterile
paperpoint tip, (Meta Biomed Co., Elmhurst, NY). The samples were
mixed with 100 μl PBS and stored frozen at −80 °C for subsequent
protein analysis. Samples used for bacterial count analysis were
placed at 4 °C and the samples were then distributed within 2 hours
onto blood agar plates.
To quantitate bacterial load, 10 μl of the post-debridement
wound ﬂuid supernatant was serially diluted (10−2 to 10−7),
then streaked onto blood agar plates, and incubated aerobically in
5% CO2 at 37 °C for 24 hours. The number of colony-forming units
(CFUs) on each plate was counted. Bacterial species were identiﬁed
by standard microbiological techniques, including Gram stain,
automated identiﬁcation of isolates (Vitek2, Biomérieux) and
susceptibility testing of Staphylococcus aureus isolates to determine
methicillin-resistance. Previous studies in our laboratory have
veriﬁed the reproducibility of sampling in a post-debridement
wound ﬂuid sample by this method (Xu et al., 2007). For matrix
metalloproteinase determination, frozen wound ﬂuids were thawed
and analyzed for wound ﬂuid MMP-2 and MMP-9, by zymography
using established techniques (Liu et al., 2009).
As an external control, ulcer healing results were compared with
the cohort of recently treated historical controls (n = 84) derived
from high risk foot clinic patients with ulcers, subject to the same
inclusion/exclusion criteria and receiving ongoing care in the same
HRFS. Notably, the standard of care provided in the HRFS had not
changed from the historic controls and the propolis treated series. All
study subjects who would have qualiﬁed for the propolis study and
who were treated in the same HRFS but were treated in recent years
prior to study recruitment for the propolis active treatment, were
included as controls. This historic control group of n = 84, was
derived from across 2008 to 2010 calendar years. During those years
the standardized approach to treating DFU in the clinic was the same
as in 2011–2012 inclusive, and attendant senior medical, nursing and
allied health staff were similar and in continuity across the 5 years.
Treatment consisted of careful assessment of ulcer precipitating and
predisposing factors with ulcer classiﬁcation, followed by multidisci-
plinarymanagement including pressure off-loading, debridement and
dressings, and treatment of clinical infection, all as previously
described in our Service (Xu et al., 2007) and following international
Table 1
Demographicandtreatedulcerdetailsof thepropolis treatedandhistoric controlpopulations.
Control Propolis
Patient number (n) 84 24
Males (%) 76.2 84.0
Age (years) 63.1 ± 13.7 58.1 ± 11.2
Type 2 diabetes (%) 86.9 77.3
Diabetes duration (years) 17.7 ± 16.5 18.3 ± 9.2
Smoker (%) – Current or past 62.3 63.6
HbA1c level (%) 8.8 ± 2.0 8.2 ± 1.6
Previous amputation (%) Yes 15.7 32.0
Previous foot ulcer (%) Yes – any 59.6 56.0
Ulcer area (mm2) 219 ± 326 240 ± 561
University of Texas grade (%) 1 71.3 77.3
2 or 3 28.7 22.7
University of Texas stage (%) A 21.3 31.8
B 65.0 54.5
C or D 13.7 13.7
Ulcer type (%) Neuropathic 78.6 66.7
Neuro-ischemic 9.5 25.0
Post-surgical or
pressure/trauma
11.9 8.3
A recurrent ulcer site (%) Yes 21.5 13.6
Antibiotic therapy – oral (%) 80 75
Data are expressed where shown as prevalence (%) or as mean ± SD.
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Fig. 1.Overallwoundhealing outcomes. (A): Percentagewound area compared tooriginal
size per week in propolis vs. historic control populations. Results are mean ± SEM. Ulcer
area was reduced in the propolis group compared with the control group at week 1
(*P b 0.001), and at week 3 (**P b 0.05), respectively by Mann–Whitney U-test.
(B): Percentage of patients whose ulcers had healed per week in propolis vs. historic
control populations. Results are mean ± SEM. *P b 0.05 by chi-squared test. The shaded
areas in each graph reﬂect the propolis treatment period in the propolis treated group.
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propolis as described earlier, received topical propolis in addition to
this foot ulcer care. While hyperbaric oxygen (HBO) therapy has an
evidence-base to support its use in DFU care (Liu, Li, Yang, Boden, &
Yang, 2013) especially in recalcitrant non-healing DFU, it is not our
usual practice nor that of others (Cavanagh et al., 2005), to use such
therapy routinely, and no DFU in the propolis or control group was
treated with HBO therapy in these series.
Comparison of the control subjects with propolis treated
subjects showed that in general the two groups were similar in
demographic and ulcer characteristics (Table 1). Notably, the
diabetes duration and gender distribution were not different, nor
were the HbA1c level documented at the time of clinic therapy, or a
history of past foot ulceration. The average patient age and number
of subjects in the propolis group who had type 2 diabetes were
lower than the control group data, but neither reached statistical
signiﬁcance. The ulcer area, mainly forefoot site, University of Texas
staging and grading of ulcers (Oyibo et al., 2001) were each similar
among the propolis and control groups (Table 1). However, the
propolis group had a ~ two fold higher rate of historic amputation
(usually a digit), and a more than two-fold greater prevalence of
neuroischemic based ulceration, compared with the control group,
while the control group had a higher rate of recurrent ulceration
(Table 1). Overall, the demographic and ulcer data were similar
between groups and they are consistent with those reported by
others in recent international literature where DFUs were managed
at a high risk foot clinic (Oyibo et al., 2001; Prompers et al., 2008).
In considering treatments provided, for oral antibiotic therapy
(Table 1), there was little variation between the control and propolis
treated groups, with 80 and 75% respectively being on oral antibiotic
treatment at study recruitment. Anti-S. aureus antibiotic therapy
predominated in each group with n = 66 of 84, and 18 of 24
respectively in each group receiving treatment. Patients in both
groups received routine, appropriate optimized ofﬂoading for their
ulcer type (ofﬂoading types included CAM walkers, post operative
shoes, felt padding, medical grade footwear and total contact
orthoses) (Liu et al., 2009). The types of dressings used in the 2
groups were also similar as per the HRFS approach to wound care,
with almost all patients in each group receiving foam dressings
(mainly Biatain™) and occasionally, anti-microbial dressings (mainly
Iodosorb™) (Liu et al., 2009).3. Statistical analysis
All data are expressed as mean ± standard error of the mean, and
are articulated in a linear scale. The presentation of MMP data is
transformed logarithmically in order to realize a graphically-accessible
dependent variable in this data set. T-tests (two tailed) and chi-squared
testwere used for demographics in Table 1, andMann–Whitney U-tests
were undertaken for ulcer healing rate, bacterial count between group
comparisons, and MMP changes between groups, as data for each were
not normally distributed. The chi-squared test was also used in
comparing % of ulcers healed per time point.
4. Results
4.1. Ulcer healing
The main ulcer end-points examined across propolis and control
groups were the rate of healing and the percentage of ulcers
progressively fully healed in the study period. At weeks 1 and 3
propolis treated ulcers had a signiﬁcantly greater healing rate
compared with the control group (Fig. 1A). Ulcer area was reduced
853F.R. Henshaw et al. / Journal of Diabetes and Its Complications 28 (2014) 850–857by amean 41% in the propolis group comparedwith 16% in the control
group at week 1 (P b 0.001), and by 63 vs. 44% at week 3, respectively
(P b 0.05), each by Mann–Whitney U-test. Subsequently, after
propolis treatment was completed, the residual wound area and
ulcer healing rates converged between the two groups (Fig. 1A). The
percentage of patients whose ulcers were fully healed at weeks 4, 5
and 7 was higher in the propolis treated group than the controls,
Fig. 1B. At weeks 4 and 5, 10 vs. 2% (P b 0.001), then by week 7, 13 vs.
5% (P b 0.05) of propolis treated vs. control ulcers had fully healed,
respectively. As per the ulcer healing rate, after propolis therapy had
been completed, the curves for the percentage of ulcers that had
healed converged for the propolis and control groups (Fig. 1B).
In a pre-planned exploratory analysis, study subjects were sub-
divided into twogroups, those thatwere treatedwith antibiotic therapy,(A)
(B)
(C)
Fig. 2. Wound healing outcomes based on concurrent antibiotic therapy. (A): Propolis vs. hi
(B): Comparisons in the control population who were receiving antibiotic concurrent oral
propolis treated population whowere receiving antibiotic concurrent oral antibiotic therapy
*P b 0.001 and **P b 0.05 vs. respective comparator during the same treatment week, by Mand thosewhowere not. Ulcers of patientswhowere receiving systemic
antibiotic therapy as well as topical propolis (n = 16) showed
improved healing rate at weeks 1, 3 and 4 compared with ulcers that
received systemic antibiotics only (n = 66), with *P b 0.001 at week 1,
and **P b 0.05 at weeks 3 and 4, by Mann Whitney U-test, Fig. 2A. No
such differences were seen when the non-antibiotic treated control
group (n = 18) andpropolis treatedulcerswithout antibiotics (n = 8),
were compared (not shown). Control group ulcers receiving no
antibiotics showed accelerated healing at weeks 2 and 3 compared
with control group antibiotic treated wounds (each **P b 0.05 by
Students t-test, Fig. 2B). In contrast, no differences were observed
within the propolis treated ulcers for those receiving antibiotic or non-
antibiotic therapy, as per Fig. 2C. As addressed in the subsequent
discussion, only clinically infected ulcers in the Propolis study were(n=66)
(n=18)
(n=66)
(n=16)
(n=16)
(n=8)
storic control populations each of whom were receiving concurrent antibiotic therapy.
antibiotic therapy compared with the controls who were not. (C): Comparisons in the
compared with the propolis treated whowere not. In each case, results are mean ±SEM.
ann–Whitney U-test.
854 F.R. Henshaw et al. / Journal of Diabetes and Its Complications 28 (2014) 850–857treated with antibiotic therapy. These data, although limited by sample
size, suggests that propolis may particularly help healing of antibiotic
treated, clinically infected ulcers.
4.2. Bacterial load and proﬁle
In subgroup analysis, bacterial load was compared early after
treatment between visit 1 and 2 in subjects treated with propolis.
After treatment with propolis, the number of colony forming units
(CFU's) counted was reduced per week by 17%, from 118 to 88 CFU's
in the propolis treated group. While this change was not statistically
signiﬁcant, possibly related to small sample size and inter-individual
variation in data, it represents a 26% reduction in bacterial burden in
the wound across 10 days (Fig. 3). In general, across visits 1 and 2, all
bacterial species reported appear to have reduced in CFU counts
(Fig. 3). This rate of change of CFU data was compared with CFU
counts in ulcer ﬂuid obtained from 32 patients with neuropathic
ulcers from our previous study published in 2007 (Xu et al., 2007).
This latter cohort comprised similar patients whowere referred to the
same HRFS as the propolis study and received similar care. The CFU
count showed a signiﬁcant change across 10 days of −26% in the
propolis treated group, comparedwith a reduction of less than−1% in
the published control group (P b 0.001, by Mann Whitney U-test).
4.3. MMP-2 and MMP-9 changes in wound ﬂuid
Wound ﬂuid samples from propolis treated study participants were
analyzed by gelatin zymography. By this techniques and shown in the
representative image (Fig. 4A) it is possible to determine the type of
MMP and its functional status. The smaller form ofMMP is the activated
MMP and in this work referred to as ‘active’ MMP while the form with
higher molecular weight is biologically latent and is termed the pro
MMP. Also shown in Fig. 4A are representative results from a propolis
treated ulcer, where changes in active MMP-9 are observed from visit 1
to visit 2, each run in duplicate. The change of active MMP-2 and -9Fig. 3. Effect of propolis on post-debridement wound ﬂuid viable bacteria. The pie charts sho
2. The relative area of each pie chart in (A) and (B) reﬂects relative CFU counts. The differing b
each respective visit, totaling 100% for all bacteria combined. The average time difference blevels were calculated as a percentage change per 10 days. Rate of
change inwound area (%)was also calculated over the sameperiod. The
MMP data were normalized by log transformation and expressed as %
changebetweenvisits 1 and2, and visits 2 and3.As shown in Fig. 4, from
visits 1 to 2, activeMMP-9 fell in thepropolis treatedulcers (Fig. 4B), and
wasunchanged fromvisits 2 to 3 (Fig. 4C). ActiveMMP-2 didnot change
across the intervals studied(Fig. 4 andC), and theamountsof pro-MMP-9
or pro-MMP-2 were also not altered (not shown).
These data were compared with a subgroup of patients (n = 39)
who were seen at the same time-points as the Propolis treated cohort,
thatwere a subgroupof thehistoric controls referred to for ulcer healing
in the current report (Suk et al., 2009). For this analysis archived results
for wound ﬂuid MMP levels at the initial and subsequent visits were
assessed as a rate of change between visits as described. The active
MMP-9 levels decreased at a signiﬁcantly faster rate in the propolis
treated group when compared with the control group in the ﬁrst time
period (visits 1 and 2), P b 0.05 byMann–Whitney U-test (% change per
10 days log10 −0.68 for propolis vs. 2.64 for controls), Fig. 4B. This
pattern was maintained in the second time period (visits 2 and 3),
P b 0.005 although the magnitude of the change was not as great
(% change/10 days, 0.05 for propolis vs. 0.64 in controls). Across each
time period, no differences in rate of change of active MMP-2 were
observed between propolis and the controls, as shown in Fig. 4B and C.4.4. Tolerability and safety
There were no adverse effects observed in any of the propolis
treated study subjects including absence of cutaneous allergy. In
personal communication, all regular staff at the foot Clinic indicated
that the administration of propolis to a foot ulcer added to normal
care had no adverse impact on the day-to-day activities of the Clinic.
The staff stated that they would consider using propolis routinely as
a topical wound therapy after it had been formally tested in a
randomized controlled trial in diabetic foot ulcers.Visit 1      
(%)
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(%)
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Fig. 4. MMP-2 and MMP-9 changes in post-debridement wound ﬂuid. (A): Representative zymography image showing pro- and active-MMP-2 and MMP-9 with standards, for a
patient ulcer treated with propolis, with samples run in duplicate for visits 1 and 2; active-MMP-9 signal is seen to fall from visit 1 to visit 2. ActiveMMP-9 and active MMP-2 changes
from (B) visit 1 to visit 2 and (C) visit 2 to 3, each per 10 days are shown, in control and propolis treated wounds across the visits indicated. Data aremean ± SEM. The y-axis data are
log transformed in each case. At visits 1–2 and 2–3 active MMP-9 change was signiﬁcantly different in the propolis treated group compared with controls; *P b 0.05 and **P b 0.005
respectively compared with controls, by Mann Whitney U-test. No such differences were seen in MMP-2 levels.
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The known anti-inﬂammatory and anti-bacterial properties of
propolis combined with positive preclinical data in diabetic ulcers
(McLennan et al., 2008) make it a natural target for a human wound
healing study in diabetes. Previous studies of propolis have indicated
that it has low allergenicity to humans (Rajpara et al., 2009), low
ﬁnancial cost and shows wound healing acceleration in a diabetic rat
model (McLennan et al., 2008). The current single site, prospective,
externally controlled study demonstrates that propolis is generally
well tolerated by patients, it is straightforward to apply by staff, and it
has ﬁndings of efﬁcacy in ulcer healing. Both initial ulcer healing rate
and healing completeness, as well as wound microenvironment
measures of active MMP-9 and bacterial count were improved by
propolis. To our knowledge, while individual case reports have
implicated propolis as having a role in diabetic ulcers (Lotfy, Badra,
Burham, & Alenzi, 2006), this is the ﬁrst report on outcome of a series
of systematically treated diabetic foot ulcers.It is notable that the effect of proplis was most clearly seen within
some weeks of its ﬁrst topical application. Advantage of propolis on
ulcer healing rate was seen at weeks 1 and 3, and on overall healing
on week 4. These quite rapid effects are consistent with the known
potent anti-inﬂammatory effects of propolis, and its efﬁcacy in the
rodent model of diabetic ulcer healing. The current pilot study was
designed to optimally detect these early differences. In contrast, the
ulcer healing rates began to rapidly converge after propolis
treatment had completed (after week 6), as did the overall ulcer
healing rate. These data suggest that the effect of propolis is
relatively transient. It is unknown whether the efﬁcacy of propolis
observed during its application would have persisted if the therapy
was maintained.
The primary aim of this pilot studywas to evaluate the effectiveness
of recurrent administration of topical propolis in a patient series. An
indication of effect size, feasibility, acceptability and adverse events, of
topical propolis in chronic diabetic foot ulcers was also sought. Propolis
application with each HRFS clinic visit demonstrated no adverse effects
856 F.R. Henshaw et al. / Journal of Diabetes and Its Complications 28 (2014) 850–857onpatients or their ulcers, and its usewaswell acceptedby regular clinic
staff. In using the data acquired, predictions of an appropriate sample
size and related study design can be made for a future full scale
randomized controlled study of proplis in diabetic foot ulcers. The
current pilot feasibility study was not powered to determine if propolis
may be effective in foot ulcer healing. It did however show that propolis
was safe, well tolerated and easy to use and that propolis may have
efﬁcacy in diabetic foot ulcer healing. Sheehan and colleagues reported
that achieving50% inwoundhealing areabyweek4 is a robustpredictor
of long termhealing prognosis (Sheehan, Jones, Giurini, Caselli, & Veves,
2006). That is, if a diabetic foot ulcer wound is not 50% healed at week 4
then there is only a 9% chance it will be healed completely within
3 months. Power calculations based on this pilot study show that in
order for propolis treated wounds to show a 40% improvement in
healing compared with wounds receiving standard care at week 4 with
conﬁdence level of 0.95, that is for the propolis treated group to be
30% of original size and control wounds to be 50% of original size, also
with variance as in this study, for 80% power, n = 103 subjects would
need to be recruited in each arm of a randomized controlled study of
propolis vs. control.
Signiﬁcant improvement in healing rate was seen in the overall
cohorts and when the antibiotic treated control and propolis
subgroups were compared. No such differences were seen among
the two non-antibiotic treated groups. It is also possible that the
effects of propolis are predominant in clinically infected ulcers as they
required antibiotic therapy. It should be noted that all of the propolis
treated ulcers deemed clinically infected, as per Texan staging at 67%
(n = 16 of 24), were each treated with antibiotics, and that our
Service have a low threshold for prescribing and maintaining ongoing
antibiotic therapy until ulcer healing. No clinically uninfected ulcers in
the propolis study were treated with antibiotics. This subgroup
ﬁnding is consistent with the known anti-bacterial effects of propolis
(Astani et al., 2013). In addition, in the control group, healing rates
were greater at weeks 2 and 3 in the wounds that did not receive
antibiotic therapy. It is logical that these wounds in the control group
healed more rapidly because they lacked the complicating factor of
infection. This situation was not seen in the propolis treated infected
wounds. The healing rate between the antibiotic treated and non-
antibiotic treated propolis treated wounds was similar. This ﬁnding
further supports the concept that the anti-bacterial properties of
propolis have prevented the delay in healing that would otherwise
occur in the infected wounds. They support the recent ﬁnding that
propolis potentiates the potency of most antibiotics, especially those
active against S. aureus (Wojtyczka et al., 2013). Future studies should
examine these preliminary data, in a larger, randomized controlled
trial design.
Propolis had demonstrable antibacterial effect in this study. The
bacterial load (CFU) in propolis treated ulcers decreased by 26% in
diabetic wound ﬂuid over 10 days compared with b1% in a subgroup of
published controls. Studies by our laboratory found that increased
bacterial count predicts poor wound healing in neuropathic ulceration,
the predominant ulcer type in this study (Xu et al., 2007). Multiple
studies have previously elucidated that propolis is able to reduce
bacteria in wounds (Erkmen & Ozcan, 2008; Kosalec, Pepeljnjak,
Bakmaz, & Vladimir-Knezevic, 2005; Mihai et al., 2012), mainly with
bacteriostatic activity (Drago et al., 2000). This is particularly the case for
Pseudomonas aeruginosa (Farnesi, Aquino-Ferreira, De Jong, Bastos, &
Soares, 2009; Pepeljnjak & Kosalec, 2004). Our pilot studywas too small
to examine effects on speciﬁc bacterial species. Studies have explored
themode of action of propolis and found that ethanol extract of propolis
(EEP) is able to regulate gene expression of bacteria; EEP is able to
signiﬁcantly affect the LasA and LasB (staphylolytic endopeptidases
secreted by P. aeruginosa) gene expression and protease activities
(Morales et al., 2011). These changes in the bacterial protease activity
were observed with no signiﬁcant effects on survival of the organism.
This ﬁnding suggests the need for further investigations to be made onthe effect of EEP on the maturation and differentiation of bacterial
bioﬁlms, including in vivo.
The protease MMP-9 in wound ﬂuid has importance as a marker,
and a potential mediator, of foot ulcer healing in diabetes. High
levels of active MMP-9 have been shown to correlate with poor
wound healing and to predict future non-healing (Ladwig et al.,
2002; Liu et al., 2009). Reductions in the expression of MMP-9
preclinically, correlatewith increasedwound healing and percentage
of collagen in wounds in a diabetic rat model (Aparecida Da Silva
et al., 2013) and caffeic acid phenyl ester (CAPE) a component of
propolis has potent ability to inhibit the protein concentration of pro-
inﬂammatory proteinase, matrix metalloproteinase-9 in vitro (MMP-
9) (Ladwig et al., 2002). In the current study propolis treatedwounds
showed signiﬁcantly greater reductions in the active MMP-9
compared with an untreated control subgroup. How propolis causes
this change is uncertain and whether some of the actions are via
effects on regulators of MMP activities such as the tissue inhibitors of
metalloproteinases are possible mechanisms.
Propolis contains more than 180 separate compounds and while its
ingredients differ based on plants in different geographic regions
accessed by propolis making bees, the main active components are
thought to be present in all forms of propolis (Wagh, 2013a). The
current study used a readily available commercial source of propolis.
Propolis' anti-inﬂammatory effects are largely attributable to CAPE
(Ladwig et al., 2002; Nagaoka et al., 2003; Natarajan, Singh, Burke,
Grunberger, & Aggarwal, 1996; Russo et al., 2002) and its anti-bacterial
activity is thought to be mainly due to the phenolic acid fraction
(Wojtyczka et al., 2013). Robust evidence exists to support the anti-
microbial properties of propolis. It has an inhibitory concentration that
is 400 times greater than tetracycline's against Escherichia coli andmore
than 50 times higher against S. aureus and Bacillus subtilis (Bonvehi &
Coll, 1994). Propolis has also been shown to inhibit the proliferation of
fungal elements such as Candida albicans (Metzner, Schneidewind, &
Friedrich, 1977) and viruses (Gekker et al., 2005).
Despite its potential as an agent to improve outcomes in many
disease states, published blinded randomized controlled trials of
topical cutaneous propolis therapy are notably lacking. Other topical
therapies in DFU healing also hold promise, such as uncontrolled
pilot studies of certain impregnated protease inhibitor ulcer
dressings (Richard et al., 2012) and anti-bacterial iodine based
preparations (Schwartz et al., 2013). Furthermore, treatments such
as topical phenytoin impregnated dressings have shown some
efﬁcacy in small, randomized studies in DFU (Shaw, Hughes, Lagan,
& Bell, 2007), although subsequent high quality randomized
controlled trial has not shown beneﬁt (Shaw et al., 2011). While a
clinical trial with blinding of a propolis treatment group would
be difﬁcult due to its characteristic color and odor, the current
work can be used as the justiﬁcation for a larger scale, multicentre,
likely open label, randomized controlled trial to determine if
propolis, in combination with wound care to an international
standard (Cavanagh et al., 2005) undertaken in a multidisciplinary
high risk foot service setting (Xu et al., 2007), signiﬁcantly improves
the healing of diabetic foot ulcers compared with standardized
wound care alone. This current pilot demonstrates that recurrent
topical propolis therapy is well tolerated and feasible and that
randomized controlled trial assessment of topical propolis appears to
be warranted in diabetic foot ulcers.
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